Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Movahed, Ali ^a   Nabipour, Iraj ^a   Lieben Louis, Xavier ^b,c,d   Thandapilly, Sijo Joseph ^b,c,d   Yu, Liping ^b,c   Kalantarhormozi, Mohammadreza ^a   Rekabpour, Seyed Javad ^a   Netticadan, Thomas ^b,c,d  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b The Inst of Cardiovascular Sciences   (Canada)

^c AGRICULTURE AND AGRI FOOD CANADA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; RESVERATROL; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY INJURY; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SUPPLEMENTATION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84885354265     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/851267     Document Type: Article

References (43)

1. Herman W. H., Zimmet P., Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care 2012 35 943 944
2. Lam D. W., LeRoith D., The worldwide diabetes epidemic. Current Opinion in Endocrinology, Diabetes and Obesity 2012 19 2 93 96 2-s2.0-84858288248 10.1097/MED.0b013e328350583a
3. Forbes J. M., Cooper M. E., Mechanisms of diabetic complications. Physiological Reviews 2013 93 137 188
4. Stolar M., Glycemic control and complications in type 2 diabetes mellitus. American Journal of Medicine 2010 123 S3 S11 2-s2.0-77449089099 10.1016/j.amjmed.2009.12.004
5. Louis X. L., Thandapilly S. J., MohanKumar S. K., Yu L., Taylor C. G., Zahradka P., Netticadan T., Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. Journal of Nutritional Biochemistry 2012 23 1163 1169 2-s2.0-82255196504 10.1016/j.jnutbio.2011.06.010
6. Lin Y., Sun Z., Current views on type 2 diabetes. Journal of Endocrinology 2010 204 1 1 11 2-s2.0-73949146152 10.1677/JOE-09-0260
7. Thandapilly S. J., Louis X. L., Yang T., Stringer D. M., Yu L., Zhang S., Wigle J., Kardami E., Zahradka P., Taylor C., Anderson H. D., Netticadan T., Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. European Journal of Pharmacology 2011 668 1-2 217 224 2-s2.0-80052051692 10.1016/j.ejphar.2011.06.042
8. International Diabetes Federation, IDF Diabetes Atlas Update 2012 Brussels, Belgium International Diabetes Federation
9. Hussain A., Vaaler S., Sayeed M. A., Mahtab H., Ali S. M. K., Khan A. K. A., Type 2 diabetes and impaired fasting blood glucose in rural Bangladesh: a population-based study. European Journal of Public Health 2007 17 3 291 296 2-s2.0-34548409668 10.1093/eurpub/ckl235 (Pubitemid 47356291)
10. Freeman J. S., The increasing epidemiology of diabetes and review of current treatment algorithms. Journal of the American Osteopathic Association 2010 110 7 eS2 eS6 2-s2.0-77957239745
11. Azizi F., Gouya M. M., Vazirian P., Dolatshahi P., Habibian S., Screening for type 2 diabetes in the Iranian national programme: a preliminary report. Eastern Mediterranean Health Journal 2003 9 5-6 1122 1127 2-s2.0-17144389359 (Pubitemid 40521257)
12. Haghdoost A. A., Rezazadeh-Kermani M., Sadghirad B., Baradaran H. R., Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. Eastern Mediterranean Health Journal 2009 15 3 591 599 2-s2.0-69949171192
13. Yu W., Fu Y., Wang W., Cellular and molecular effects of resveratrol in health and disease. Journal of Cellular Biochemistry 2012 113 3 752 759 2-s2.0-84857576016 10.1002/jcb.23431
14. Juhasz B., Varga B., Gesztelyi R., Kemeny-Beke A., Zsuga J., Tosaki A., Resveratrol: a multifunctional cytoprotective molecule. Current Pharmaceutical Biotechnology 2010 11 8 810 818 2-s2.0-79954627959 10.2174/138920110793262079
15. Juric D., Wojciechowski P., Das D. K., Netticadan T., Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. American Journal of Physiology 2007 292 5 H2138 H2143 2-s2.0-34250857969 10.1152/ajpheart.00852.2006 (Pubitemid 47084592)
16. Thandapilly S. J., Wojciechowski P., Behbahani J., Louis X. L., Yu L., Juric D., Kopilas M. A., Anderson H. D., Netticadan T., Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. American Journal of Hypertension 2010 23 2 192 196 2-s2.0-75549083493 10.1038/ajh.2009.228
17. Sharma S., Misra C. S., Arumugam S., Roy S., Shah V., Davis J. A., Shirumalla R. K., Ray A., Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytotherapy Research 2011 25 1 67 73 2-s2.0-78650636700 10.1002/ptr.3221
18. Ramadori G., Gautron L., Fujikawa T., Vianna C. R., Elmquist J. K., Coppari R., Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009 150 12 5326 5333 2-s2.0-71949100263 10.1210/en.2009-0528
19. Szkudelski T., Szkudelska K., Anti-diabetic effects of resveratrol. Annals of the New York Academy of Sciences 2011 1215 1 34 39 2-s2.0-78851469053 10.1111/j.1749-6632.2010.05844.x
20. Do G. M., Jung U. J., Park H. J., Kwon E. Y., Jeon S. M., McGregor R. A., Choi M. S., Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Molecular Nutrition & Food Research 2012 56 1282 1291
21. Bhatt J. K., Thomas S., Nanjan M. J., Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research 2012 32 537 541
22. Brasnyó P., Molnár G. A., Mohás M., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition 2011 106 3 383 389 2-s2.0-80052910300 10.1017/S0007114511000316
23. Crandall J. P., Oram V., Trandafirescu G., Reid M., Kishore P., Hawkins M., Cohen H. W., Barzilai N., Pilot study of resveratrol in older adults with impaired glucose tolerance. The Journals of Gerontology A 2012 67 1307 1312
24. Timmers S., Konings E., Bilet L., Houtkooper R. H., Van De Weijer T., Goossens G. H., Hoeks J., Van Der Krieken S., Ryu D., Kersten S., Moonen-Kornips E., Hesselink M. K. C., Kunz I., Schrauwen-Hinderling V. B., Blaak E. E., Auwerx J., Schrauwen P., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism 2011 14 5 612 622 2-s2.0-80455143206 10.1016/j.cmet.2011.10.002
25. Poulsen M. M., Vestergaard P. F., Clasen B. F., Radko Y., Christensen L. P., Stodkilde-Jorgensen H., Moller N., Jessen N., Pedersen S. B., Jorgensen J. O., High-dose resveratrol supplementation in obese men: an investigator- initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013 62 4 1186 1195
26. Bruckbauer A., Zemel M. B., Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes, Metabolic Syndrome and Obesity 2013 6 93 102
27. Burtis C. A., Ashwood E. R., Carbohydrates. Tietz Textbook of Clinical Chemistry 1999 Philadelphia, Pa, USA W.B Saunders 750 808
28. Friedewald W. T., Levy R. I., Fredrickson D. S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 6 499 502 2-s2.0-0015348189
29. Jeppsson J., Kobold U., Barr J., Finke A., Hoelzel W., Hoshino T., Miedema K., Mosca A., Mauri P., Paroni R., Thienpont L., Umemoto M., Weykamp C., Approved IFCC reference method for the measurement of HbA1c in human blood. Clinical Chemistry and Laboratory Medicine 2002 40 1 78 89 2-s2.0-18244404332 10.1515/CCLM.2002.016 (Pubitemid 34196455)
30. Sapin R., Le Galudec V., Gasser F., Pinget M., Grucker D., Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro. Clinical Chemistry 2001 47 3 602 605 2-s2.0-0035107402 (Pubitemid 32222484)
31. Matthews D. R., Hosker J. P., Rudenski A. S., Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 7 412 419 2-s2.0-0021813187 (Pubitemid 15018832)
32. Vang O., Ahmad N., Baile C. A., Baur J. A., Brown K., Csiszar A., Das D. K., Delmas D., Gottfried C., Lin H., Ma Q., Mukhopadhyay P., Nalini N., Pezzuto J. M., Richard T., Shukla Y., Surh Y., Szekeres T., Szkudelski T., Walle T., Wu J. M., What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 2011 6 6 2-s2.0-79959261445 10.1371/journal.pone.0019881 e19881
33. Smoliga J. M., Baur J. A., Hausenblas H. A., Resveratrol and health-a comprehensive review of human clinical trials. Molecular Nutrition and Food Research 2011 55 8 1129 1141 2-s2.0-79961047423 10.1002/mnfr.201100143
34. Genovesi S., Brambilla P., Giussani M., Galbiati S., Mastriani S., Pieruzzi F., Stella A., Valsecchi M. G., Antolini L., Insulin resistance, prehypertension, hypertension and blood pressure values in paediatric age. Journal of Hypertension 2012 30 2 327 335 2-s2.0-84855844680 10.1097/HJH.0b013e32834e4aaa
35. Brown V. A., Patel K. R., Viskaduraki M., Crowell J. A., Perloff M., Booth T. D., Vasilinin G., Sen A., Schinas A. M., Piccirilli G., Brown K., Steward W. P., Gescher A. J., Brenner D. E., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Research 2010 70 22 9003 9011 2-s2.0-78549288940 10.1158/0008-5472.CAN-10-2364
36. Ghazanfari Z., Haghdoost A. A., Alizadeh S. M., Atapour J., Zolala F., A comparison of HbA1c and fasting blood sugar tests in general population. International Journal of Preventive Medicine 2010 1 3 187 194 2-s2.0-79952064151
37. Hirst J. A., Farmer A. J., Ali R., Roberts N. W., Stevens R. J., Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012 35 2 446 454 2-s2.0-84859097414 10.2337/dc11-1465
38. Wallace T. M., Levy J. C., Matthews D. R., Use and abuse of HOMA modeling. Diabetes Care 2004 27 6 1487 1495 2-s2.0-2542469144 10.2337/diacare.27.6.1487 (Pubitemid 38680001)
39. Sone H., Tanaka S., Iimuro S., Ishibashi S., Oikawa S., Shimano H., Katayama S., Ohashi Y., Akanuma Y., Yamada N., Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study. Diabetes Care 2012 35 1150 1157
40. Bonakdaran S., Ebrahimzadeh S., Noghabi S. H., Cardiovascular disease and risk factors in patients with type 2 diabetes mellitus in Mashhad, Islamic Republic of Iran. Eastern Mediterranean Health Journal 2011 17 9 640 646 2-s2.0-80052753082
41. MayoClinic, Niacin to Boost Your HDL, "Good" Cholesterol 2011 Rochester, Minn, USA MayoClinic
42. Keidan B., Hsia J., Katz R., Plasma lipids and antidiabetic agents: a brief overview. British Journal of Diabetes and Vascular Disease 2002 2, article 3
43. Brookes S. T., Whitley E., Peters T. J., Mulheran P. A., Egger M., Smith G. D., Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technology Assessment 2001 5 33 1 56 2-s2.0-0034799451